Drug intelligence / Profile preview

AD-2112

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules

Overview

AD-2112 is a small molecule drug candidate developed for the treatment of pain. Its mechanism of action is as an agonist of the mu-opioid receptor (OPRM), which is a well-established target for analgesic therapies. The drug does not represent a novel mechanism in pain management and, as of now, has not received regulatory approval in any country. Clinical development has included at least one completed Phase 1 trial involving healthy volunteers and subjects with unspecified pain. No known adverse events have been reported to date[1].

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on AD-2112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2112.

Explore the full profile